CoChat

Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin

Open access
Jonassen, Ib, Havelund, Svend, Hoeg-Jensen, Thomas, Steensgaard, Dorte Bjerre, Wahlund, Per-Olof, Ribel, Ulla · 2012 · Pharmaceutical Research

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

PURPOSE: Basal insulins with improved kinetic properties can potentially be produced using acylation by fatty acids that enable soluble, high-molecular weight complexes to form post-injection. A series of insulins, acylated at B29 with fatty acids via glutamic acid spacers, were examined to deduce the structural requirements. METHODS: Self-association, molecular masses and hexameric conformations of the insulins were studied using size exclusion chromatography monitored by UV or multi-angle light scattering and dynamic light scattering, and circular dichroism spectroscopy (CDS) in environments (changing phenol and zinc concentration) simulating a pharmaceutical formulation and changes following subcutaneous injection. RESULTS: With depletion of phenol, insulin degludec and another fatty diacid-insulin analogue formed high molecular mass filament-like complexes, which disintegrated with depletion of zinc. CDS showed these analogues adopting stable T(3)R(3) conformation in presence of phenol and zinc, changing to T(6) with depletion of phenol. These findings suggest insulin degludec is dihexameric in pharmaceutical formulation becoming multihexameric after injection. The analogues showed weak dimeric association, indicating rapid release of monomers following hexamer disassembly. CONCLUSIONS: Insulins can be engineered that remain soluble but become highly self-associated after injection, slowly releasing monomers; this is critically dependent on the acylation moiety. One such analogue, insulin degludec, has therapeutic potential.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11095-012-0739-z

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Schematic representation of insulin degludec. DesB30 human insulin was acylated at the ε-amino group of LysB29 with hexadecandioic acid via a γ-L-glutamic acid linker. The structural elements of the ligand were examined for their impact on the ability of the resulting insulin analogue to form multihexamers (Table I).
Fig. 1 Schematic representation of insulin degludec. DesB30 human insulin was acylated at the ε-amino group of LysB29 with hexadecandioic acid via a γ-L-glutamic acid linker. The structural elements of the ligand were examined for their impact on the ability of the resulting insulin analogue to form multihexamers (Table I).CC BY · PubMed Central
Fig. 2 Schematic representation of insulin-zinc hexamer conformation. In a typical pharmaceutical formulation insulin adopts the relaxed (R) conformation. Upon depletion of phenol after injection the poles will subsequently (one pole at a time) adopt the tense (T) conformation, exposing the core and zinc ions. Ultimately zinc dissociates and the hexamer disassembles into dimers and insulin monomers.
Fig. 2 Schematic representation of insulin-zinc hexamer conformation. In a typical pharmaceutical formulation insulin adopts the relaxed (R) conformation. Upon depletion of phenol after injection the poles will subsequently (one pole at a time) adopt the tense (T) conformation, exposing the core and zinc ions. Ultimately zinc dissociates and the hexamer disassembles into dimers and insulin monomers.CC BY · PubMed Central
Fig. 3 Size exclusion chromatography (SEC) evidence of various insulin degludec self-association states. Insulin degludec was analysed by SEC in the absence of phenol employing a Sepharose 6HR column after formulation with an increasing number of zinc ions per six insulin degludec molecules (panel A). The proportion eluting as multihexamers was closely related to the zinc content. Panel B shows the reciprocal change in the monomer and multihexamer content going from phenol-containing formulations ranging from zero to six zinc ions per six insulin degludec molecules. The traces show the mean and minimum and maximum values (as bars) from duplicate analyses. Near identical values were obtained in each analysis. The lowermost trace in panel A shows SEC of an insulin degludec formulation in the presence of phenol employing a Sepharose 12GL column. Insulin degludec elutes with a peak corresponding to an insulin dihexamer. The small peak that elutes at approximately 44 min corresponds to a molecular weight of 118 kDa. The peak at approximately 78 min does not contain protein. Panel C shows the molar mass distributions of insulin degludec and octadecandioyl-γ-L-Glu desB30 human insulin at two different zinc concentrations in the presence of phenol determined by SEC-MALS. Solid lines in the chromatograms represent traces from the RI detector, dotted lines show the molar mass distribution. The buffer used is without phenol and contains 10 mM Tris–HCl, pH 7.4, 140 mM NaCl.
Fig. 3 Size exclusion chromatography (SEC) evidence of various insulin degludec self-association states. Insulin degludec was analysed by SEC in the absence of phenol employing a Sepharose 6HR column after formulation with an increasing number of zinc ions per six insulin degludec molecules (panel A). The proportion eluting as multihexamers was closely related to the zinc content. Panel B shows the reciprocal change in the monomer and multihexamer content going from phenol-containing formulations ranging from zero to six zinc ions per six insulin degludec molecules. The traces show the mean and minimum and maximum values (as bars) from duplicate analyses. Near identical values were obtained in each analysis. The lowermost trace in panel A shows SEC of an insulin degludec formulation in the presence of phenol employing a Sepharose 12GL column. Insulin degludec elutes with a peak corresponding to an insulin dihexamer. The small peak that elutes at approximately 44 min corresponds to a molecular weight of 118 kDa. The peak at approximately 78 min does not contain protein. Panel C shows the molar mass distributions of insulin degludec and octadecandioyl-γ-L-Glu desB30 human insulin at two different zinc concentrations in the presence of phenol determined by SEC-MALS. Solid lines in the chromatograms represent traces from the RI detector, dotted lines show the molar mass distribution. The buffer used is without phenol and contains 10 mM Tris–HCl, pH 7.4, 140 mM NaCl.CC BY · PubMed Central
Fig. 4 Circular dichroism spectroscopy (CDS) assessment at 251 nm of the allosteric interconversion of insulin degludec and human insulin with increasing phenol concentration. The insulin concentration was 0.6 mM containing six Zn2+ per six insulin degludec and two Zn2+ per six insulin in Tris-perchlorate 10 mM, pH 8.0. Degludec obtains T3R3 conformation at 10 mM phenol but remains unchanged thereafter. Human insulin obtains R6 conformation at 30 mM phenol.
Fig. 4 Circular dichroism spectroscopy (CDS) assessment at 251 nm of the allosteric interconversion of insulin degludec and human insulin with increasing phenol concentration. The insulin concentration was 0.6 mM containing six Zn2+ per six insulin degludec and two Zn2+ per six insulin in Tris-perchlorate 10 mM, pH 8.0. Degludec obtains T3R3 conformation at 10 mM phenol but remains unchanged thereafter. Human insulin obtains R6 conformation at 30 mM phenol.CC BY · PubMed Central
Fig. 5 Schematic representation of the hypothesis for the mode of retarded absorption of insulin degludec: Insulin degludec is injected subcutaneously as a zinc phenol formulation containing insulin degludec dihexamer in the T3R3 conformation. Rapid loss of phenol changes the degludec hexamers to T6 configuration and multi-hexamer chains form. With slow diffusion of zinc, these chains break down into dimers, which quickly dissociate into readily-absorbed monomers.
Fig. 5 Schematic representation of the hypothesis for the mode of retarded absorption of insulin degludec: Insulin degludec is injected subcutaneously as a zinc phenol formulation containing insulin degludec dihexamer in the T3R3 conformation. Rapid loss of phenol changes the degludec hexamers to T6 configuration and multi-hexamer chains form. With slow diffusion of zinc, these chains break down into dimers, which quickly dissociate into readily-absorbed monomers.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Research works printed but not linked: 3

  1. Kruger P, Gilge G, Cabuk Y, Wollmer A. Cooperativity and intermediate states in the T;R-structural transformation of insulin. Biol Chem Hoppe Seyler. 1990;371:669–73. · DOI
  2. Heise T, Hermanski L, Nosek L, Feldmann A, Rasmussen S, Stryhn TK, Haahr H. Insulin degludec: less pharmacodynamic variability than insulin glargine under steady state conditions. Diabetologia. 2010;53(Suppl1):S387.
  3. Kurzhals P, Heise T, Strauss HM, Bøttcher SG, Granhall C, Haahr H, Jonassen I. Multi-hexamer formation is the underlying mechanism behind the ultra-long glucose-lowering effect of insulin degludec. Diabetes. 2011;60 Suppl 1:LB12.

Cited by

See all 475

Metadata

Authors
Jonassen, I., Havelund, S., Hoeg-Jensen, T., Steensgaard, D. B., Wahlund, P.-O., & Ribel, U.
Affiliations
Novo Nordisk (Denmark) (DK)
Corresponding author
Jonassen, Ib
Venue
Pharmaceutical Research
Published
2012-04-07
Volume
29
Issue
8
Pages
2104-2114
ISSN
  • 0724-8741 (ISSN-L)
  • 1573-904X
OpenAlex
W1986874694
Cited by
448
References
32
Citations by year
2026: 7 · 2025: 19 · 2024: 24 · 2023: 19 · 2022: 28 · 2021: 40 · 2020: 24 · 2019: 33 · 2018: 33 · 2017: 30 · 2016: 35 · 2015: 49 · 2014: 45 · 2013: 45 · 2012: 16
FWCI
19.91
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Pharmaceutical Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Novo Nordisk
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords
insulin degludec, fatty acid acylation, insulin conformation, subcutaneous injection, insulin analogues
MeSH terms
Acylation, Amino Acid Sequence, Chromatography, Gel, Circular Dichroism, Fatty Acids, Humans, Hypoglycemic Agents, Insulin, Models, Molecular, Molecular Sequence Data, Protein Binding, Serum Albumin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin. https://app.cochat.ai/papers/10.1007/s11095-012-0739-z
The paper
Jonassen, I., Havelund, S., Hoeg-Jensen, T., Steensgaard, D. B., Wahlund, P.-O., & Ribel, U. (2012). Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin. Pharmaceutical Research. https://doi.org/10.1007/s11095-012-0739-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.